German patients "would pay more" for diagnosis
This article was originally published in Clinica
Executive Summary
Some 61% of the German public questioned by survey company tns healthcare said that they would pay out of their own pocket for diagnostic tests that the statutory sickness funds do not cover. The survey, carried out on July 7 on behalf of the diagnostics industry association VDGH, found varying levels of readiness to pay: a quarter would pay another Euro50 ($58) annually for such preventive measures; another 23% would pay Euro100 more, and another 29% up to Euro200 or more.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.